Is SV40 in the COVID Vaccine? What the Evidence Shows

The live SV40 virus is not an ingredient in any COVID-19 vaccine. What has been detected, and what has fueled a persistent online controversy, is something more mundane but genuinely worth understanding: short fragments of a DNA sequence originally borrowed from the SV40 virus, found as trace manufacturing residue in Pfizer’s mRNA vaccine specifically. The gap between “SV40 contamination” and “residual fragments of an SV40-derived lab sequence” is enormous, and the distinction matters for anyone trying to evaluate the actual risk.

SV40 the Virus Versus SV40 the Sequence

Simian virus 40, or SV40, is a real virus that naturally infects certain monkey species. In laboratory research decades ago, scientists discovered that a small stretch of this virus’s DNA is remarkably good at driving gene expression in mammalian cells. That short stretch, known as the SV40 promoter-enhancer, became one of the most widely used tools in molecular biology. It has been a standard component of laboratory plasmids (small circular DNA molecules used as workhorses in genetic research and manufacturing) for over 40 years. The promoter-enhancer is a regulatory sequence, a DNA “on switch” that tells cellular machinery to read a nearby gene. It does not encode the SV40 Large T antigen, the viral protein responsible for SV40’s ability to cause tumors in hamster experiments.

This distinction is critical. The T antigen protein can bind to and disable p53, a key human tumor suppressor, and it carries the enzymatic machinery SV40 uses to replicate its own DNA.¹ The promoter-enhancer sequence does none of those things. It is a stretch of DNA that functions as a molecular address label, not as an infectious agent or an oncogene. When people say “SV40 is in the COVID vaccine,” they are conflating a snippet of repurposed DNA with the virus it came from.

How the Sequence Ended Up in Pfizer’s Vaccine

Making an mRNA vaccine starts with a DNA template. Manufacturers build a circular plasmid that contains the gene for the target protein (in this case, the SARS-CoV-2 spike protein), then use that plasmid as a template to produce mRNA through a process called in vitro transcription. Once the mRNA has been made, the DNA template is no longer needed and gets enzymatically digested. Most of it is broken down into tiny fragments and washed away during purification, but trace amounts survive as residual impurities in the final product.²

Pfizer’s manufacturing plasmid happened to include the SV40 promoter-enhancer sequence. This is a routine choice in molecular biology: the sequence is an efficient tool for plasmid maintenance and gene expression during the production phase. Moderna, by contrast, used a different plasmid design that did not include the SV40 element. That difference is why SV40 promoter-enhancer fragments have been detected in Pfizer’s vaccine but not in Moderna’s.

The presence of the SV40 sequence in Pfizer’s plasmid was not hidden, but it also was not prominently communicated to the public. The regulatory submissions to agencies like the FDA and EMA contained the plasmid maps, but the SV40 element did not receive the same level of public-facing explanation as, say, the lipid nanoparticle components. When independent researchers later flagged its presence, the lack of proactive disclosure fed suspicion, even though the sequence itself had a prosaic manufacturing purpose.

What Independent Testing Has Found

Several independent research groups have tested COVID-19 mRNA vaccine vials for residual DNA, and their results do not entirely agree, which is part of what makes this topic confusing.

A Canadian study that analyzed multiple Pfizer and Moderna vials reported finding the SV40 promoter-enhancer sequence in all tested Pfizer vials, at levels ranging from about 0.25 to 23.72 nanograms per dose. Moderna vials showed no detectable SV40 sequence. The same study measured specific plasmid DNA targets at 0.22 to 7.28 nanograms per dose in Pfizer and 0.01 to 0.78 nanograms per dose in Moderna. DNA fragment sizes averaged around 214 base pairs, with the longest fragment reaching about 3,500 base pairs.²

A separate analysis published in NPJ Vaccines tested 15 batches of both Pfizer’s Comirnaty and Moderna’s Spikevax vaccines using four different measurement methods, including quantitative PCR and fluorometry. That study found residual DNA in all batches to be below the 10-nanogram-per-dose regulatory limit, with no evidence of excessive DNA contamination in any sample.³ A third analysis specifically confirmed that the DNA-to-RNA mass ratio in the vaccines was approximately 1 to 1,000, consistent with what the manufacturers declared in their regulatory filings.²

Why the Numbers Disagree

The discrepancy between studies is not a sign that someone is lying. It comes down to measurement technique. The NPJ Vaccines study documented a serious technical pitfall: when using fluorometry (a common method for measuring DNA quantities), the enormous amount of mRNA in the vaccine can bind to the DNA-detecting dyes and generate a false signal, inflating the apparent DNA count. Unless researchers first destroy the RNA with an enzyme before measuring, the fluorometric reading can be dramatically too high.³ The Canadian study that reported higher total DNA values (up to roughly 1,500 nanograms per dose for Pfizer and over 6,000 for Moderna) used fluorometry, and those headline-grabbing total DNA figures likely reflect this kind of RNA cross-contamination of the measurement. The specific plasmid DNA targets measured by the more precise quantitative PCR method in the same study were orders of magnitude lower.

This matters because the scariest-sounding numbers circulating online tend to come from the total DNA measurements rather than the specific plasmid DNA measurements, conflating background signal with actual contaminant levels.

Regulatory Limits and Whether They Were Exceeded

The World Health Organization and the U.S. FDA have long recommended that residual DNA in biological products stay below 10 nanograms per dose, with fragments no longer than 200 base pairs.⁴ These limits were set conservatively for traditional vaccines manufactured in continuous cell lines, where the concern was that host-cell DNA from potentially tumorigenic cell substrates might carry active oncogenes. The context for mRNA vaccines is somewhat different: the residual DNA comes from a well-characterized plasmid, not from a potentially cancerous cell line. Nonetheless, the same thresholds have been applied.

The multi-method NPJ Vaccines study found all 15 tested batches of Comirnaty and Spikevax fell below the 10-nanogram limit across every method used.³ The Canadian study, however, reported that two out of six tested Pfizer lots (three vials) exceeded the regulatory limit for the SV40 promoter-enhancer sequence specifically, by roughly two-fold.²

Whether that finding represents a genuine quality-control failure or a methodological difference is still debated. The fragment-size data from the Canadian study showed an average of 214 base pairs, close to the 200-base-pair guideline, with most fragments far shorter than a functional gene. Even the longest detected fragment at 3,500 base pairs is small relative to a complete plasmid or a functional oncogene. The fragment sizes matter because very short stretches of DNA are far less biologically active than intact genes or plasmids.

Could These DNA Fragments Do Anything Harmful?

This is the central safety question, and it breaks into two parts: could the DNA fragments get into cell nuclei, and if so, could they integrate into the human genome or drive unwanted gene expression?

The SV40 promoter-enhancer sequence is known to facilitate nuclear import of plasmid DNA in laboratory settings. Research has shown that plasmids containing the SV40 enhancer are more efficiently transported into cell nuclei than plasmids without it, particularly in non-dividing cells.⁵ In animal experiments involving gene delivery to blood vessels, plasmids carrying the SV40 sequence showed increased nuclear localization and higher gene expression compared to those without it.⁶

These findings are real and come from respected labs, but they describe intact plasmids deliberately engineered and delivered for gene therapy purposes, not tiny degraded fragments suspended alongside a huge payload of mRNA. The nuclear pore complex, which controls what enters the nucleus, blocks the passive entry of more than 97 percent of DNA that reaches the cell’s interior.⁷ The SV40 enhancer can improve those odds for intact plasmids, but the fragments in vaccine doses are overwhelmingly short, degraded remnants of the original plasmid, not complete functional units. A 200-base-pair fragment carrying part of an enhancer is a fundamentally different entity from a 5,000-base-pair intact plasmid designed for nuclear entry.

On the integration question, a comprehensive evidence review concluded that residual DNA levels in mRNA vaccines fall within established regulatory limits when measured with validated methods, and that no credible mechanism supports genomic integration from these fragments.⁸ For a DNA fragment to integrate into a human chromosome, it would need to enter the nucleus, find a double-strand break in the genomic DNA to slip into, and survive without being destroyed by the cell’s repair enzymes. Each of those steps is individually unlikely for a short, degraded fragment; the probability of all three occurring together is vanishingly small.

A hypothesis paper has raised the possibility that vaccine mRNA could be reverse-transcribed by endogenous retrotransposons (the cell’s own “jumping gene” elements), which would theoretically create DNA copies of the vaccine sequence inside cells. That concern is based on a single in vitro study and remains speculative; the same broad evidence review found no support for this mechanism leading to any detectable clinical harm.⁸

The Polio Vaccine Parallel

Part of the alarm around “SV40 in vaccines” draws emotional power from a real historical episode. Between 1955 and 1963, tens of millions of people received polio vaccines that were genuinely contaminated with live SV40 virus. The virus had been growing undetected in the monkey kidney cells used to produce the vaccine.⁹ Since SV40 can cause tumors in hamsters, the discovery raised obvious fears about cancer in the millions of people who had been exposed.

Decades of follow-up have produced mixed signals. A large epidemiological study found no significant increase in cancer rates among birth cohorts exposed to SV40-contaminated polio vaccine, including no elevated risk of brain cancers or osteosarcoma.¹⁰ A different analysis of the same era reported modestly increased rates of certain cancers in exposed cohorts, including ependymomas, bone tumors, and mesothelioma.¹¹ The scientific community has debated these findings for decades without reaching a clean consensus, though the weight of evidence leans toward no significant cancer signal from the polio-era contamination.

The comparison to mRNA COVID vaccines is misleading in a fundamental way. The polio vaccines contained live, replication-competent SV40 virus, complete with the T antigen and all other viral proteins. COVID-19 mRNA vaccines contain degraded fragments of a non-coding regulatory sequence that was never part of a live virus in the first place. Invoking the polio-era SV40 story to argue that COVID vaccines carry cancer risk is like comparing a functioning engine to a small piece of scrap metal that was once stamped in the same factory.

Pfizer Versus Moderna on This Specific Issue

Moderna’s vaccine manufacturing process used a plasmid that did not include the SV40 promoter-enhancer element, which is why the SV40 sequence has not been detected in any tested Moderna vials.² Both vaccines still contain trace residual plasmid DNA, because the enzymatic digestion step can never be 100 percent efficient, but the composition of that residual DNA differs based on whatever plasmid the manufacturer started with.

If the SV40 sequence specifically concerns you, the straightforward practical answer is that it was never present in Moderna’s product. But the broader point is that residual plasmid DNA of any origin is a standard and expected impurity in biologics manufacturing, managed through regulatory limits rather than eliminated entirely. The presence of plasmid fragments per se is not unique to mRNA vaccines or to COVID vaccines in particular.

How the Concern Spread

The SV40-in-vaccines narrative gained traction through a familiar pattern: a legitimate scientific finding was stripped of its context, amplified through social media, and fused with preexisting distrust. Analysis of online discourse around mRNA vaccine safety found that scientific references were frequently blended with unsupported claims, including fears of genome alteration and population control. Positive sentiment toward the vaccines was rare in these discussions, and users tended to interpret any new study as confirmation of their existing skepticism.¹²

The kernel of truth, that Pfizer’s manufacturing plasmid contained an SV40-derived sequence and that fragments of this sequence survived into some vaccine doses, is real and worth investigating. The leap from there to “the COVID vaccine contains a cancer virus” requires ignoring essentially everything known about what the SV40 promoter-enhancer actually is, how degraded the residual fragments are, and what it would take for those fragments to cause harm. The overall body of evidence, including multi-method analyses of vaccine batches and broad safety assessments, does not support increased long-term mortality, cancer, autoimmune disease, or genotoxicity from mRNA COVID-19 vaccination.⁸

Lipid Nanoparticles and the Delivery Question

One concern that occasionally surfaces in more technically oriented discussions is whether the lipid nanoparticles (LNPs) used to deliver vaccine mRNA might also deliver residual DNA fragments into cells more efficiently than naked DNA would be delivered on its own. LNPs are designed to fuse with cell membranes and release their cargo into the cytoplasm, so any DNA fragments encapsulated alongside the mRNA would, in theory, also end up inside cells.

The Canadian study estimated that individual vaccine doses contained between roughly 100 million and 160 billion plasmid DNA fragments encapsulated in LNPs.² That sounds like a large number in absolute terms, but it represents a tiny fraction of the total LNP cargo, which is dominated by mRNA molecules. And reaching the cytoplasm is not the same as reaching the nucleus. Research into DNA-based gene therapy has shown that even when DNA is deliberately delivered into cells using optimized LNP formulations, the nuclear pore complex blocks the vast majority from entering the nucleus, which is why gene therapy researchers have been actively trying to solve this problem with specialized peptides and targeting strategies.⁷ The accidental presence of degraded DNA fragments in a vaccine is a very different scenario from the deliberate, engineered nuclear delivery that gene therapy requires.

You can think of it this way: getting DNA into the cytoplasm of a cell is the easy part. Getting it past the nuclear envelope, intact, and in a form that can actually do something biologically meaningful is the hard part, so hard that entire fields of research exist to try to make it work on purpose. The residual fragments in vaccines have not been engineered to overcome any of those barriers. They are manufacturing debris, not a delivery system.